18F-BMS-986,229与18F-BMS-986,192在晚期非小细胞肺癌中的PD-L1 PET/CT显像
本研究在IV期非小细胞肺癌患者中比较新型PD-L1 PET示踪剂18F-BMS-986,229与18F-BMS-986,192的肿瘤摄取,并分析其与PD-L1免疫组化及临床结局的相关性。两种示踪剂肿瘤摄取表现相当,平均SUVpeak分别为2.75(SD 1.53)与2.68(SD 1.78),p=0.780。肿瘤示踪剂摄取与PD-L1免疫组化不相关,低SUVpeak可能排除长期总生存,值得进一步研究。
要点
- 18F-BMS-986,229与18F-BMS-986,192肿瘤摄取表现相当。
- 肿瘤示踪剂摄取与PD-L1免疫组化不相关。
- 低SUVpeak可能排除长期总生存,需进一步验证。
核心结论
- 18F-BMS-986,229与18F-BMS-986,192肿瘤摄取表现相当。
- 在本小样本队列中,基线PD-L1示踪剂摄取与PD-L1免疫组化不相关。
- 低肿瘤示踪剂摄取可能与较短总生存相关,值得进一步研究。
研究设计与样本
- IV期非小细胞肺癌患者接受基线PET/CT扫描,分别使用18F-BMS-986,229与18F-BMS-986,192两种示踪剂。
- 采用SUVpeak和SUVmean定量示踪剂摄取。
- 影像结果与肿瘤活检PD-L1表达及临床结局(最佳总体缓解和总生存)进行相关性分析。
主要发现
- 18F-BMS-986,192与18F-BMS-986,229平均SUVpeak分别为2.75(SD 1.53)与2.68(SD 1.78),p=0.780。
- PD-L1 tps<50%组平均SUVpeak为3.77,PD-L1≥50%组为3.54,p=0.8175。
- 探索性分析显示低SUVpeak排除长期总生存,较高SUVpeak不能区分短或长总生存。
临床怎么用
- 基线PD-L1 PET/CT显像可用于评估肿瘤示踪剂摄取,但当前结果不支持其替代PD-L1免疫组化。
- 低肿瘤示踪剂摄取可能提示较短总生存,可作为预后评估的探索性参考。
局限性
- 本研究为小样本队列。
- 肿瘤示踪剂摄取与总生存的关联为探索性分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Predicting response to checkpoint inhibitors in non-small cell lung cancer (NSCLC) remains challenging. In addition to programmed death-ligand 1 (PD-L1) immunohistochemistry (IHC), PD-L1 imaging could improve response prediction. This study evaluated a novel PD-L1 PET tracer, 18F-BMS-986,229, and compared its performance to 18F-BMS-986,192, which shares the same target. METHODS: Stage IV NSCLC patients were scheduled for baseline PET/CT scans with both tracers. Tracer uptake was quantified using SUVpeak and SUVmean. Imaging findings were correlated with PD-L1 expression from tumor biopsies and clinical outcomes, including best overall response and overall survival. RESULTS: 18F-BMS-986,192 and 18F-BMS-986,229 performed equally with respect to tumor tracer uptake. Mean SUVpeak was 2.75 (SD 1.53) vs. 2.68 (SD 1.78), p = 0.780. Tumor tracer uptake did not correlate with PD-L1 IHC, mean SUVpeak in the PD-L1 tps < 50% group was 3.77 vs. 3.54 in the PD-L1 ≥ 50% group (p = 0.8175). Explorative analysis of the association between tumor tracer uptake and OS revealed that a low SUVpeak excluded a long OS, whereas a higher SUVpeak did not discriminate between patients with a short or long OS. CONCLUSION: 18F-BMS-986,229 and 18F-BMS-986,192 performed equally with respect to tumor uptake. In this small cohort, baseline PD-L1 tracer uptake did not correlate with PD-L1 IHC. Low tumor tracer uptake may be associated with shorter overall survival, warranting further investigation. CLINICAL TRIAL REGISTRATION: NCT03001882, https//clinicaltrials.gov/study/NCT03001882.
引用
- Smit J, Borm FJ, Gerards NR, et al. PD-L1 PET/CT imaging with 18F-BMS-986,229 and 18F-BMS-986,192 in patients with advanced-stage non-small cell lung cancer. Eur J Nucl Med Mol Imaging. 2026. PMID: 42809016. doi:10.1007/s00259-026-08188-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。